Trial · NCT00773357

Modeling Stress-precipitated Smoking Behavior for Medication Development

NCT00773357, Phase 2, Completed, Yale University; results first posted 2022-08-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Modeling Stress-precipitated Smoking Behavior for Medication Development. Trials, record NCT00773357. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00773357

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Modeling Stress-precipitated Smoking Behavior for Medication Development
NCT number: NCT00773357
Status: Completed
Phases: Phase 2
Enrollment: 100 participants, actual
Lead sponsor: Yale University
Conditions: Smoking
Interventions: guanfacine, placebo
First posted: 2008-10-16
Last updated: 2022-08-03
Results first posted: 2022-08-01

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Latency to Initiate Ad-lib Smoking Session	50 minutes	latency to initiate smoking (in minutes) during a 50-minute period.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Latency to Initiate Ad-lib Smoking Session	50 minutes		minutes	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Latency to Initiate Ad-lib Smoking Session	Guanfacine		31.55	Standard Error 5.30	minutes
Latency to Initiate Ad-lib Smoking Session	Placebo		30.31	Standard Error 5.44	minutes

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Guanfacine	50
Overall Study	STARTED	Placebo	50
Overall Study	COMPLETED	Guanfacine	50
Overall Study	COMPLETED	Placebo	50
Overall Study	NOT COMPLETED	Guanfacine	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	dry mouth	General disorders	Guanfacine	35	50
other	dry mouth	General disorders	Placebo	12	50
other	Drowsiness	General disorders	Guanfacine	19	50
other	Drowsiness	General disorders	Placebo	9	50
other	Dizziness	Nervous system disorders	Guanfacine	5	50
other	Dizziness	Nervous system disorders	Placebo	4	50
other	Headache	Nervous system disorders	Guanfacine	15	50
other	Headache	Nervous system disorders	Placebo	10	50
other	Impotence	Reproductive system and breast disorders	Guanfacine	1	50
other	Impotence	Reproductive system and breast disorders	Placebo	1	50

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Guanfacine	0	50
Total, all-cause mortality	Placebo	0	50
Total, other adverse events	Guanfacine	35	50
Total, other adverse events	Placebo	12	50
Total, serious adverse events	Guanfacine	0	50
Total, serious adverse events	Placebo	0	50

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants4

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
U54AA027989	Yale-SCORE on Sex Differences in Alcohol Use Disorder	MCKEE, SHERRY ANN	YALE UNIVERSITY	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM	2020 to 2025	NIH RePORTER
P01AA027473	Sex-Appropriate Treatment Development for Alcohol Use Disorders	MCKEE, SHERRY ANN	YALE UNIVERSITY	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM	2018 to 2019	NIH RePORTER
P50DA033945	Yale SCOR on Gender-Sensitive Treatment for Tobacco Dependence	MCKEE, SHERRY ANN	YALE UNIVERSITY	NATIONAL INSTITUTE ON DRUG ABUSE	2012 to 2017	NIH RePORTER
RL1DA024857	Modeling Stress-Precipitated Smoking Lapse for Medication Development (9 of 14)	MCKEE, SHERRY ANN	YALE UNIVERSITY	NATIONAL INSTITUTE ON DRUG ABUSE	2007 to 2011	NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Guanfacine vs Placebo: deaths from any cause	Trial comparisons
Guanfacine vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00773357

GET https://conductscience.org/api/trials/v1/NCT00773357/registered

API reference For AI assistants